GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ovctek China Inc (SZSE:300595) » Definitions » EBIT

Ovctek China (SZSE:300595) EBIT : ¥871 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ovctek China EBIT?

Ovctek China's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥246 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥871 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ovctek China's annualized ROC % for the quarter that ended in Mar. 2024 was 24.10%. Ovctek China's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 55.91%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ovctek China's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.28%.


Ovctek China EBIT Historical Data

The historical data trend for Ovctek China's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovctek China EBIT Chart

Ovctek China Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 334.27 462.55 684.27 795.93 857.24

Ovctek China Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.71 172.33 298.16 154.03 246.35

Competitive Comparison of Ovctek China's EBIT

For the Medical Instruments & Supplies subindustry, Ovctek China's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovctek China's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ovctek China's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ovctek China's EV-to-EBIT falls into.



Ovctek China EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥871 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovctek China  (SZSE:300595) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ovctek China's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=883.152 * ( 1 - 12.83% )/( (3118.422 + 3271.284)/ 2 )
=769.8435984/3194.853
=24.10 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5518.911 - 338.351 - ( 2062.138 - max(0, 584.1 - 3693.983+2062.138))
=3118.422

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5730.115 - 317.295 - ( 2141.536 - max(0, 566.76 - 3813.796+2141.536))
=3271.284

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ovctek China's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=985.38/( ( (636.598 + max(1076.104, 0)) + (678.87 + max(1133.333, 0)) )/ 2 )
=985.38/( ( 1712.702 + 1812.203 )/ 2 )
=985.38/1762.4525
=55.91 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(241.69 + 160.033 + 1181.084) - (338.351 + 0 + 168.352)
=1076.104

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(278.35 + 162.75 + 1176.878) - (317.295 + 0 + 167.35)
=1133.333

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ovctek China's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=870.872/13859.345
=6.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovctek China EBIT Related Terms

Thank you for viewing the detailed overview of Ovctek China's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovctek China (SZSE:300595) Business Description

Traded in Other Exchanges
N/A
Address
No. 4899 Wangjiang West Road, High-tech Zone, Anhui Province, Hefei, CHN, 230088
Ovctek China Inc is a China-based company engaged in the research and development, production, and sales of rigid gas permeable contact lens products. Its products include Hard Mirror, Mirror Teshu family, High-end ophthalmic products, and Security products. The company-owned trademarks are DreamVision, DreamDawei, Ri Dawei, Hua Cone, Jing Teshu, openvision, and Mengshiqing among others.
Executives
Tao Yue Qun Directors, executives
Directors, executives
Yin Yin Director

Ovctek China (SZSE:300595) Headlines

No Headlines